A new study conducted by researchers from the Washington University School of Medicine identified an experimental drug that ...

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with ...

The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab ( Leqembi) and donanemab ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

A study examining the long-term effects of anti-amyloid therapy gantenerumab suggests that full amyloid plaque removal may help reduce Alzheimer’s symptoms in individuals at risk for dominantly ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

Scientists report long-term gantenerumab use might prevent cognitive decline in people with genetic predisposition to ...

An experimental drug has shown promise in preventing Alzheimer’s for people at higher risk of developing the disease.

A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...